



**ARECOR'S CEO DISCUSSES THE COMPANY'S INNOVATIVE FORMULATION TECHNOLOGY PLATFORM  
AND  
ITS PARTNERSHIP WITH THE LONDON STOCK EXCHANGE'S ELITE PROGRAMME  
FOR GROWTH COMPANIES**

**Cambridge, UK.**, 10 May 2017: Arecor Ltd ("the Company"), the UK-based leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides enabling the improved treatment of diabetes and other conditions, is pleased to report on a recent interview between Dr Sarah Howell, Chief Executive Officer of Arecor and Zarina Nasib, UK Manager of the London Stock Exchange's ELITE Programme for growth companies.

The interview can be viewed on the following link:

<https://uk.elite-growth.com/en/content/news/watch-sarah-howell-ceo-arecor-speak-about-their-innovative-product-diabetes-and-share>

In her interview, Dr Howell discusses Arecor's innovative and proprietary formulation technology platform, from which it produces superior biopharmaceutical products via a dual business model.

- Firstly, under a profitable technology licensing model, Arecor works with pharmaceutical companies on products within their pipeline, to which it applies the Arecor technology to develop superior product profiles or product formats for its partners that would otherwise not be possible.
- Secondly, and more recently, Arecor has been leveraging its technology platform to develop superior products for diabetes care, which the Company itself is taking forward into clinical development.

**In terms of future goals and in what looks to be a busy and exciting year ahead, Sarah Howell outlines how Arecor will look to continue to grow its technology licensing division along with its revenues and profits over the period; will seek to bring additional talent into the business, and she adds,** *"On the back of some great data we have generated over the last year on our diabetes products, we will be working hard to get those products into the clinic and to be dosing patients in a clinical trial by early 2018".*

**In terms of challenges there are always risks in terms of product development, but as Dr Howell observed,** *"We are taking existing products where the safety and effectiveness of the products is already known and we are repurposing them with the aim of taking them to market, with the key here being that we*



*are delivering product concepts that are simply not achievable elsewhere and we are meeting critical unmet medical needs as far as glucagon is concerned”.*

*“Our long-term ambition is to create a leading global specialty pharma company based in the UK. We will continue to leverage off our technology platform and develop superior products with our partners through the strategy of repurposing products and then ultimately, taking those products to market ourselves. We have a clear strategic vision and plan in place for Arecor and on the successful execution of our plan, we would expect to deliver significant value to our shareholders”.*

**\*\*\* ENDS \*\*\***

**For more information, please contact:**

**Arecor Limited**

[www.arecor.com](http://www.arecor.com)

Dr Sarah Howell, Chief Executive

Tel: +44 (0) 1223 426 060

**Peckwater PR**

[tarquin.edwards@peckwaterpr.co.uk](mailto:tarquin.edwards@peckwaterpr.co.uk)

Tarquin Edwards

Tel: +44 (0) 7879 458 364

**About Arecor**

Arecor Ltd is a leader in developing superior biopharmaceuticals through the application of an innovative formulation technology platform. Arecor is currently leveraging this platform to develop a portfolio of proprietary products that will enable improved treatments for diabetes via the innovative reformulation of approved proteins and peptides. Arecor's product portfolio also includes:

- Stable aqueous glucagon for emergency and artificial pancreas use,
- Novel insulin formulations to deliver ultra-rapid acting insulin analogs and;
- Ultra-concentrated rapid acting insulin to enable the miniaturisation of devices.

In addition to its internal product portfolio, Arecor partners with leading pharmaceutical and biotech companies to deliver superior reformulations of their proprietary products, which would otherwise not be possible using conventional formulation science.

**About ELITE**

ELITE is a full-service programme designed to help ambitious companies prepare and structure for the next stage of growth through the access to long term financing opportunities. It is a unique offering for scale-ups across Europe and beyond, providing a comprehensive training programme and extensive access to the business and financial community. The ELITE Club Deal private placement platform, launched earlier in 2017, will also help streamline the capital raising process for ELITE companies.

For further information on the programme, companies and the full list of partners, please go to:

[www.elite-growth.com](http://www.elite-growth.com)